Latest News and Press Releases
Want to stay updated on the latest news?
-
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
-
–Data suggest SINTAX™ medicine may overcome blood-brain barrier limitations to anti-inflammatory drug delivery– –EDP1867 reduced disease severity and incidence of relapse in murine model of multiple...
-
–Clinically and statistically significant improvement in PASI-50 score achieved––EDP1815 safety and tolerability data comparable to placebo in study––EDP1815 advancing towards registration studies in...
-
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
-
CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new type of orally delivered medicines, today...
-
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
-
–EDP1815 Phase 2b data in psoriasis expected in 3Q 2021––Finalized design of Phase 2 clinical trial of EDP1815 in atopic dermatitis; start of trial anticipated in 3Q 2021––Strengthened leadership team...
-
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...
-
CAMBRIDGE, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced...
-
CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced...